

REPLIGEN CORP  
Form 8-K  
January 30, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report (Date of earliest event reported): January 26, 2015**

**REPLIGEN CORPORATION**  
**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**0-14656**  
**(Commission**  
**File Number)**

**04-2729386**  
**(IRS Employer**  
**Identification No.)**

**41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA**

**02453**

**(Address of principal executive offices)**

**(Zip Code)**

**Registrant's telephone number, including area code (781) 250-0111**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.02. Termination of a Material Definitive Agreement.**

On January 26, 2015, Pfizer Inc. issued to Repligen Corporation (the Company ) a notice of termination for convenience under the License Agreement, dated December 28, 2012, by and between the Company and Pfizer Inc. (the License Agreement ) for the development of compounds to treat spinal muscular atrophy (SMA). The termination of the License Agreement will become effective as of April 26, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPLIGEN CORPORATION

Date: January 30, 2015

By: /s/ Walter C. Herlihy  
Walter C. Herlihy  
President and Chief Executive Officer